Sanofi’s New CEO Faces Drug Pipeline and Policy Challenges

Sanofi’s newly appointed chief executive faces pressing challenges to revive the company’s drug development pipeline while adapting to evolving healthcare policies. Analysts suggest that accelerating innovation, strengthening clinical research, and navigating regulatory shifts will be crucial for sustaining growth. Geopolitical uncertainties and pricing reforms add complexity to the environment. Strategic partnerships and targeted acquisitions may help rebuild investor confidence and enhance long-term competitiveness.